Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-other
JIVI, is indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for: On-demand treatment and control of bleeding episodes Perioperative management of bleeding Routine prophylaxis to reduce the frequency of bleeding episodes Limitations of Use JIVI is not indicated for use in: Children < 7 years of age due to greater risk for hypersensitivity reactions and/or loss of efficacy [see Use in Specific Populations (8.4)] Previously untreated patients (PUPs) Treatment of von Willebrand disease
- generic_name
- antihemophilic factor (recombinant) pegylated-aucl
- brand_name
- water, Antihemphilic Factor (Recombinant) Pegylated-aucl
- product_names
- Antihemophilic Factor (Recombinant) Pegylated-aucl, water, Antihemphilic Factor (Recombinant) Pegylated-aucl
- ndc
- 0026-3942, 0026-3942-25, 0026-3942-99, 0026-4942, 0026-4942-01, 0026-4942-99, 0026-0426, 0026-0426-02, 0026-3944, 0026-3944-25, 0026-3944-99, 0026-4944, 0026-4944-01, 0026-4944-99, 0026-3946, 0026-3946-25, 0026-3946-99, 0026-4946, 0026-4946-01, 0026-4946-99, 0026-3948, 0026-3948-25, 0026-3948-99, 0026-4948, 0026-4948-01, 0026-4948-99, 0026-3950, 0026-3950-50, 0026-3950-99, 0026-4950, 0026-4950-01, 0026-4950-99, 0026-0426-15, 0026-0426-05
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en